1. Blood. 2022 Jun 16;139(24):3505-3518. doi: 10.1182/blood.2021014723.

Concurrent CDX2 cis-deregulation and UBTF::ATXN7L3 fusion define a novel 
high-risk subtype of B-cell ALL.

Passet M(1)(2), Kim R(1)(2), Gachet S(1), Sigaux F(1)(2), Chaumeil J(3), Galland 
A(4), Sexton T(5), Quentin S(2), Hernandez L(1), Larcher L(1)(2), Bergugnat 
H(2), Ye T(5), Karasu N(5), Caye A(6), Heizmann B(5), Duluc I(4), Chevallier 
P(7), Rousselot P(8), Huguet F(9), Leguay T(10), Hunault M(11), Pflumio F(12), 
Freund JN(4), Lobry C(1), Lhéritier V(13), Dombret H(14)(15), Domon-Dell C(4), 
Soulier J(1)(2), Boissel N(14)(15), Clappier E(1)(2).

Author information:
(1)Université Paris Cité, Institut de Recherche Saint-Louis, INSERM U944, Centre 
national de la recherche scientifique Unité mixte de recherche 7212 GenCellDi, 
Paris, France.
(2)Laboratoire d'Hématologie, Hôpital Saint-Louis, Assistance Publique-Hôpitaux 
de Paris, Paris, France.
(3)Université Paris Cité, Institut Cochin, INSERM U1016, Centre national de la 
recherche scientifique Unité mixte de recherche 8104, Paris, France.
(4)Université de Strasbourg, INSERM, Interface de recherche fondamentale et 
appliquée en cancérologie/Unité mixte de recherche-S1113, Fédération 
Hospitalo-Universitaire ARRIMAGE, ITI InnoVec, Fédération de Médecine 
Translationnelle de Strasbourg, Strasbourg, France.
(5)Université de Strasbourg, Institute of Genetics and Molecular and Cellular 
Biology, Centre national de la recherche scientifique Unité mixte de recherche 
7104, INSERM U1258, Illkirch, France.
(6)Département de Génétique, Hôpital Robert Debré, Assistance Publique-Hôpitaux 
de Paris, Université de Paris, Institut de Recherche Saint-Louis, Paris, France.
(7)Department of Hematology, Centre Hospitalo-Universitaire Nantes, INSERM Unité 
mixte de recherche1232 & Centre national de la recherche scientifique ERL6001 
Centre de Recherche en Cancérologie et Immunologie Intégrée Nantes Angers, 
Nantes, France.
(8)Department of Hematology, Centre Hospitalier de Versailles, Unité mixte de 
recherche 1184 Commissariat à l'Energie Atomique, University Paris-Saclay, Le 
Chesnay, France.
(9)Institut Universitaire du Cancer, Toulouse, France.
(10)Department of Hematology, Centre Hospitalo-Universitaire de Bordeaux, 
Hôpital du Haut-Levêque, Pessac, France.
(11)Département des Maladies du sang, Centre Hospitalo-Universitaire Angers, 
Fédération Hospitalo-Universitaire Grand Ouest Against Leukemia, Université 
d'Angers, Université de Nantes, INSERM, Centre national de la recherche 
scientifique, Centre de Recherche en Cancérologie et Immunologie Nantes-Angers, 
Structure Fédérative de Recherche Interactions Cellulaires et Applications 
Thérapeutiques, Angers, France.
(12)Laboratoire des Cellules Souches Hématopoïétiques et des Leucémies, INSERM 
U1274, Commissariat à l'Energie Atomique, Université de Paris-Université 
Paris-Saclay, Fontenay-aux-Roses, France.
(13)Coordination du Groupe Group for Research in Adult Acute Lymphoblastic 
Leukemia, Hospices Civils de Lyon, Hôpital Lyon Sud, Lyon, France.
(14)Département d'Hématologie Clinique, Hôpital Saint-Louis, Assistance 
Publique-Hôpitaux de Paris, EA-3518, Paris, France; and.
(15)Institut de Recherche Saint-Louis, Université Paris Cité, Paris, France.

Comment in
    Blood. 2022 Jun 16;139(24):3455-3457. doi: 10.1182/blood.2022015993.

Oncogenic alterations underlying B-cell acute lymphoblastic leukemia (B-ALL) in 
adults remain incompletely elucidated. To uncover novel oncogenic drivers, we 
performed RNA sequencing and whole-genome analyses in a large cohort of 
unresolved B-ALL. We identified a novel subtype characterized by a distinct gene 
expression signature and the unique association of 2 genomic microdeletions. The 
17q21.31 microdeletion resulted in a UBTF::ATXN7L3 fusion transcript encoding a 
chimeric protein. The 13q12.2 deletion resulted in monoallelic ectopic 
expression of the homeobox transcription factor CDX2, located 138 kb in cis from 
the deletion. Using 4C-sequencing and CRISPR interference experiments, we 
elucidated the mechanism of CDX2 cis-deregulation, involving PAN3 enhancer 
hijacking. CDX2/UBTF ALL (n = 26) harbored a distinct pattern of additional 
alterations including 1q gain and CXCR4 activating mutations. Within adult 
patients with Ph- B-ALL enrolled in GRAALL trials, patients with CDX2/UBTF ALL 
(n = 17/723, 2.4%) were young (median age, 31 years) and dramatically enriched 
in females (male/female ratio, 0.2, P = .002). They commonly presented with a 
pro-B phenotype ALL and moderate blast cell infiltration. They had poor response 
to treatment including a higher risk of failure to first induction course (19% 
vs 3%, P = .017) and higher post-induction minimal residual disease (MRD) levels 
(MRD ≥ 10-4, 93% vs 46%, P < .001). This early resistance to treatment 
translated into a significantly higher cumulative incidence of relapse (75.0% vs 
32.4%, P = .004) in univariate and multivariate analyses. In conclusion, we 
discovered a novel B-ALL entity defined by the unique combination of CDX2 
cis-deregulation and UBTF::ATXN7L3 fusion, representing a high-risk disease in 
young adults.

© 2022 by The American Society of Hematology.

DOI: 10.1182/blood.2021014723
PMCID: PMC9203705
PMID: 35316324 [Indexed for MEDLINE]